Moderna sees annual US market for Covid-19 shots ranging up to USD 13bn

The biotech company, which rose to fame during the pandemic, estimates that the market for Covid-19 jabs could be between USD 5.2bn and USD 13bn annually depending on prices and eligibility.

Photo: Dado Ruvic/Reuters/Ritzau Scanpix

Annual US sales of Covid-19 shots could be high as USD 12.9bn, with health officials likely recommending an annual booster, vaccine maker Moderna Inc. said in a meeting with investors.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs